Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
1	16/NE/0147	204478	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis	Range Agreed	5	20	Date Agreed	31/05/2020	6	6	31/05/2020	Recruitment finished	
2	16/NE/0413	210215	Randomised, double blind, placebo controlled, multicentre study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.	Range Agreed	3	6	Date Agreed	01/06/2020	3	3	01/06/2020	Recruitment finished	
3	14/NE/1099	144103	Phase III, Randomized, Multicenter Double-Blind, Double Dummy Study To Evaluate The Efficacy And Safety Of Etrolizumab Compared With Infliximab In Patients With Moderate To Severe Active Ulcerative Colitis Who Are Naive To TNF Inhibitors	Range Agreed	4	10	Date Agreed	31/12/2021	7	7	14/04/2020	Recruitment finished	
4	17/EE/0401	224915	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment	Range Agreed	1	3	Date Agreed	29/05/2020	2	2	29/05/2020	Recruitment finished	
5	17/YH/0391	229417	Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis	Range Agreed	2	5	Date Agreed	30/04/2020	3	3	30/04/2020	Recruitment finished	
6	18/LO/1925	250709	A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, DOUBLEDUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF UTTR1147A COMPARED WITH PLACEBO AND COMPARED WITH VEDOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Number Agreed	1	1	Date Agreed	15/10/2020	0	0	01/05/2020	Withdrawn by sponsor	
7	18/LO/1927	242927	A PHASE II OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF UTTR1147A IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS OR CROHN'S DISEASE	Range Agreed	1	2	Date Agreed	31/10/2020	0	0	01/05/2020	Withdrawn by sponsor	Following USM to suspend follow up & Recruitment Protocol amendment adds management of COVID-19 patients as well as incorporating protocol clarification letters 1 & 2. This study is pending close out, no patients were recruited or planned to be recruited
8	19/SC/0148	260130	XTEND – evaluation of an eXtended and proactive dosing regimEn in treatment-Naïve patients with wet age related macular Degeneration (wAMD)	Number Agreed	30	30	Date Agreed	15/05/2020	30	30	28/04/2020	Recruitment finished	
9	18/SW/0214	249435	A Multinational, Prospective, Observational Study of the Effectiveness, Healthcare Resource Utilization and Costs in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease-Modifying Therapies	Number Agreed	10	10	Date Agreed	31/12/2024	11	11	20/04/2020	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
10	19/EM/0220	265213	A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed	Number Agreed	2	2	Date Agreed	21/05/2020	2	2	21/05/2020	Recruitment finished	
11	18/YH/0349	243300	Pyruvate Kinase Deficiency Global Longitudinal Registry	Number Agreed	2	2	Date Agreed	28/12/2024	3	3	06/04/2020	Recruitment finished	
12	18/SC/0240	230920	A Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group, efficacy, and safety study of gantenerumab in patients with prodromal to mild Alzheimer's Disease	Range Agreed	2	4	Date Agreed	30/06/2020	2	2	19/06/2020	Recruitment finished	
13	17/SC/0345	225047	A Phase 1b, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Infections	Number Agreed	2	2	Date Agreed	01/07/2020	1	1	01/07/2020	Recruitment finished	Study closed internationally before we were able to recruit more participants
14	17/EM/0412	234907	An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients	Range Agreed	1	2	Date Agreed	20/07/2020	2	2	01/07/2020	Recruitment finished	
15	18/SW/0049	237051	A Multicenter, Open-Label, Phase 1B/2 Study to Evaluate Safety and Efficacy of Avelumab (MSB0010718C) in Combination with Chemotherapy with or without Other Anti-Cancer Immunotherapies as First-Line Treatment in Patients with Advanced Malignancies	Number Agreed	4	4	Date Agreed	06/09/2020	4	4	12/08/2020	Recruitment finished	
16	18/EM/0005	236933	An Observational Study of Blinatumomab Safety and Effectiveness, Utilisation, and Treatment Practices	Number Agreed	5	5	Date Agreed	31/03/2021	5	5	10/08/2020	Recruitment finished	
17	17/SC/0491	228055	A Phase 1-2, Open-Label, Dose-Finding, Proof Of Concept, First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of CX-2009 In Adults With Metastatic Or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)	Number Agreed	4	4	Date Agreed	31/05/2020	1	1	09/04/2020	Withdrawn by sponsor	CytomX decided to close Study CTMX-M-2009-001 to screening and enrollment, based an assessment of the continued challenges for clinical trial execution in the current COVID-19 pandemic environment and the ongoing demands the pandemic placed on the health care system
18	18/NE/0235	244048	A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)	Number Agreed	5	5	Date Agreed	31/08/2020	5	5	31/08/2020	Recruitment finished	
19	18/NE/0360	254062	An open-label, non-randomised study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy	Number Agreed	3	3	Date Agreed	18/12/2020	5	5	21/08/2020	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
20	18/SC/0392	244109	Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Pharmacokinetic Study of 2 Doses of CXA-10 on Stable Background Therapy in Subjects with Pulmonary Arterial Hypertension (PAH)	Range Agreed	2	5	Date Agreed	30/08/2020	0	0	02/07/2020	Withdrawn by sponsor	Complexa decided to terminate the study CXA-10-301 (PRIMEx) due to delays in recruitment of PRIMEx patients, creating a minimum 6 month delay due to COVID-19
21	18/LO/1859	252363	Observational cohort study of patients with hormone receptor-positive metastatic breast cancer treated with palbociclib (Ibrance®) as part of the United Kingdom Ibrance® Patient Program (IPP); the Real Outcomes Ibrance® Study (ROIS)	Range Agreed	7	13	Date Agreed	28/02/2021	10	10	03/08/2020	Recruitment finished	
22	19/NE/0076	242027	BIOTRONIKS - Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV	Range Agreed	5	15	Date Agreed	31/10/2020	9	9	14/07/2020	Recruitment finished	
23	19/NW/0001	253853	IDL-2965 – A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects with Idiopathic Pulmonary Fibrosis	Range Agreed	1	3	Date Agreed	30/06/2020	0	0	26/05/2020	Withdrawn by sponsor	Study was closed to recruitment nationally because of COVID-19
24	18/LO/1397	247266	A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis	Range Agreed	2	4	Date Agreed	12/09/2020	0	0	04/09/2020	Withdrawn by sponsor	The sponsor took a decision to terminate the program
25	19/SC/0256	263749	A 12-month prospective, randomized, interventional, global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs. oral prophylactics) in adult episodic migraine patients	Number Agreed	6	6	Date Agreed	09/10/2020	0	0	25/08/2020	Withdrawn by sponsor	In the UK we were slower to reactivate sites after the lockdown and other centers abroad recruited faster
26	19/EE/0135	252796	A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of Oral Topotecan with HM30181A Monotherapy in Patients with Advanced Malignancies	Range Agreed	6	16	Date Agreed	01/08/2020	1	1	15/06/2020	Withdrawn by sponsor	Sponsor closed recruitment unexpectedly early
27	19/NW/0504	264255	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy	Range Agreed	3	6	Date Agreed	31/10/2020	5	5	22/07/2020	Recruitment finished	
28	16/EM/0240	203358	A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma	Number Agreed	3	3	Date Agreed	01/03/2024	0	0	05/08/2020	Withdrawn by sponsor	The study closed nationally as interim analysis showed futility of the trial therapy
29	16/WM/0437	206885	A Phase 3 Multicenter, Open-label, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Range Agreed	1	3	Date Agreed	21/08/2020	2	2	21/08/2020	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
30	17/NW/0247	222303	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc in Adult Subjects with Nonalcoholic Steatohepatitis and Liver Fibrosis	Range Agreed	2	4	Date Agreed	30/09/2020	1	1	12/08/2020	Withdrawn by sponsor	The sponsor took the decision to close the AURORA study and discontinue its NASH cenicriviroc [CVC] research & development program following the completion and analysis of the Part 1 section of the AURORA Phase III study.
31	17/EE/0402	224923	A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991 Incorporating Administrative Change 1 and Amendment 1 and 2	Range Agreed	1	7	Date Agreed	12/11/2020	4	4	13/05/2020	Recruitment finished	
32	17/WM/0460	237521	PROJECT TITLE: Cabozantinib PASS Study- F-FR-60000-001 Prospective non-interventional study of cabozantinib tablets in adults with advanced renal cell carcinoma following prior vascular endothelial growth factor (VEGF)-targeted therapy.	Range Agreed	7	10	Date Agreed	30/09/2020	7	7	30/09/2020	Recruitment finished	
33	18/ES/0029	239530	A subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis	Range Agreed	2	4	Date Agreed	31/07/2021	1	1	31/12/2020	Withdrawn by sponsor	The sponsor closed to recruitment earlier than planned in December following the interim analysis
34	17/NE/0331	229957	A Prospective, Global, Multicentre, Real World Outcome Study of Fenestrated Endovascular Aneurysm Repair using the Fenestrated Anaconda™ device	Range Agreed	1	20	Date Agreed	31/12/2020	6	6	31/12/2020	Recruitment finished	
35	18/LO/0552	242687	Comprehensive Outcomes Registry in Subjects with Epilepsy Treated with Vagus Nerve Stimulation Therapy®	Number Agreed	50	50	Date Agreed	31/12/2020	14	14	31/12/2020	Withdrawn by sponsor	Sponsor closed the study early (from company end) due to commercial realignment of strategy.
36	18/NE/0292	252024	A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study	Number Agreed	4	4	Date Agreed	06/10/2020	4	4	06/10/2020	Recruitment finished	
37	19/LO/0153	259690	A randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, an oral plasma kallikrein inhibitor, in the on-demand treatment of angioedema attacks in adult subjects with hereditary angioedema type I or II	Number Agreed	2	2	Date Agreed	02/10/2020	2	2	02/10/2020	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
38	18/EM/0193	243749	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)	Number Agreed	2	2	Date Agreed	12/04/2022	1	1	31/12/2020	Recruitment finished	Recruitment finished early nationally
39	19/LO/1500	269558	Basic Evaluation Lead Post-Market Clinical Follow-up (BASIC) Study	Range Agreed	5	20	Date Agreed	31/10/2020	6	6	02/10/2020	Recruitment finished	
40	20/HRA/2191	283184	Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection "ILIAD 7 trial"	Range Agreed	1	3	Date Agreed	25/11/2020	3	3	25/11/2020	Recruitment finished	
41	20/YH/0174	283089	A randomised, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.	Number Agreed	5	5	Date Agreed	18/12/2020	2	2	13/12/2020	Recruitment finished	Recruitment ended early nationally
42	12/YH/0313	106560	A European multi-centre, multi-country, post-authorisation, observational study (registry) of patients with chronic adrenal insufficiency	Range Agreed	200	300	Date Agreed	31/12/2022	271	271	31/10/2020	Recruitment finished	
43	19/WM/0056	256301	Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease	Range Agreed	50	113	Date Agreed	30/08/2021	112	112	27/02/2021	Recruitment finished	
44	19/SC/0034	254823	A Phase 3, randomized, double-blind, parallel-group, placebo controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.	Range Agreed	3	6	Date Agreed	10/02/2021	2	2	10/02/2021	Withdrawn by sponsor	Recruitment ended early nationally
45	18/SW/0199	249896	Screening Protocol to Determine Patient Eligibility for Inclusion in AAV Gene Therapy Clinical Trials (ECLIPSE)	Number Agreed	1	1	Date Agreed	30/06/2025	1	1	26/02/2021	Recruitment finished	
46	19/EM/0072	256161	A Long-Term, Randomized, Double-Blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as needed in Response to Symptoms in Symptomatic Adults and Children 4 years of Age or Older with Asthma (MANDALA)	Range Agreed	2	4	Date Agreed	30/01/2021	3	3	30/01/2021	Recruitment finished	
47	19/LO/0357	258769	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy.	Number Agreed	4	4	Date Agreed	31/03/2021	0	0	26/03/2021	Withdrawn by PI	Chronic understaffing due to COVID meant the team were unable to find recruits for the study. The PI took the decision that it wasn't currently safe to continue with the study
48	19/NW/0716	273613	A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects	Range Agreed	1	5	Date Agreed	10/08/2021	5	5	08/02/2021	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
49	20/YH/0090	278137	AN OPEN-LABEL,MULTICENTER, ROLLOVER STUDYTO EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM ADMINISTRATION OFGANTENERUMABIN PARTICIPANTSWITHALZHEIMER'S DISEASE	Number Agreed	1	1	Date Agreed	31/10/2022	1	1	31/03/2021	Recruitment finished	
50	20/YH/0231	284781	A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA	Number Agreed	2	2	Date Agreed	15/06/2021	2	2	28/02/2021	Recruitment finished	
51	20/HRA/4325	288451	A retrospective study of the characteristics and outcomes of patients with familial chylomicronaemia syndrome treated with volanesorsen in the United Kingdom early access to medicines scheme	Range Agreed	1	2	Date Agreed	11/01/2021	1	1	11/01/2021	Recruitment finished	
52	20/EM/0142	282923	Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis B Virus (B-Clear)	Number Agreed	1	1	Date Agreed	27/08/2021	1	1	31/03/2021	Recruitment finished	
53	20/LO/0461	279984	Real-World Anti-VEGF Treatment Experience Study of the Management of Neovascular Age-Related Macular Degeneration in the UK (RATE Study in nAMD)	Range Agreed	15	20	Date Agreed	31/01/2021	17	17	31/01/2021	Recruitment finished	
54	16/LO/1637	211258	First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax®-AXL-ADC) in patients with solid tumors	Range Agreed	2	7	Date Agreed	31/10/2020	12	12	31/10/2020	Recruitment finished	
55	19/YH/0301	268446	A Phase 2 Study of ABBV-3067 Alone and in Combination with ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation	Range Agreed	2	4	Date Agreed	31/03/2021	0	0	22/03/2021	Withdrawn by sponsor	M19-530 study is now closed in the UK and Ethics has been notified of Permanent closure. Abbvie will now begin close out activities for all sites that had a finalised contract in place.
56	20/HRA/5205	289098	A PHASE I/II RANDOMIZED, TWO PARTS, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF AN INACTIVATED, ADJUVANTED SARS-COV-2 VIRUS VACCINE CANDIDATE (VLA2001), AGAINST COVID-19 IN HEALTHY INDIVIDUALS	Number Agreed	35	35	Date Agreed	15/01/2021	37	37	15/01/2021	Recruitment finished	
57	19/LO/1986	273932	AMD Barometer - Investigating patient-driven barriers to long-term anti-VEGF treatment adherence in wet AMD.	Number Agreed	9	9	Date Agreed	28/02/2021	9	9	28/02/2021	Recruitment finished	
58	18/SC/0286	246516	A Randomised, Double-blind, Parallel-group, Placebo-controlled, Phase Ia/Ib, Multiple-site Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KL1333 after a Single Oral Dose and Multiple Ascending Oral Doses in Healthy Subjects and Patients with Primary Mitochondrial Disease	Number Agreed	4	4	Date Agreed	30/11/2020	4	4	30/11/2020	Recruitment finished	